Eva Temkin Quoted in BioSpace on FDA’s Expanding Rare Disease Regulatory Framework
Eva Temkin, Arnold & Porter Life Sciences & Healthcare Regulatory partner and former Acting Policy Staff Director at the U.S. Food and Drug Administration (FDA)’s Office of Therapeutic Biologics and…
Read the full articleYou might also wanna read
Study finds significant discordance in orphan drug approvals between U.S. FDA and European Medicines Agency (2011-2023)
In a retrospective analysis, Jin Ding and colleagues explore the discrepancy in regulatory authorization of orphan drugs by U.S. and Europea
plos.io·2d ago
How excessive FDA manufacturing requirements are bottlenecking cell and gene therapy companies
Some of the most promising drugs are bottlenecked by a "boring" but incredibly important problem
writingruxandrabio.com·7d ago
Trodelvy's FDA Approval Highlights Cybersecurity Risks in Healthcare Data Infrastructure
From FDA Approval to Zero-Day Exploit: How Trodelvy’s Breakthrough Exposes Healthcare’s Cyber Achilles' Heel + Video - "Undercode Testing":
undercodetesting.com·16d ago
ASO biotech wants MHRA to go further in new rare disease therapy framework
CEO of SynaptixBio thinks the MHRA could do more to support UK rare disease drug innovation.
EMA advisor discusses real-world data and single-arm trials in oncology drug approvals
Looking forward to the future, the trends and challenges regarding the increasing utilization of real-world data and single-arm trials in th
omny.fm·5d ago
EvE Bio Releases Comprehensive Dataset Mapping FDA-Approved Drugs to Cellular Receptors
6.2k words, 29 minutes reading time
owlposting.com·8mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.